These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 25335705)

  • 1. [Tolerability and efficacy of regorafenib in patients with unresectable metastatic colorectal cancer].
    Tanaka A; Sadahiro S; Suzuki T; Okada K; Saito G
    Gan To Kagaku Ryoho; 2014 Oct; 41(10):1231-6. PubMed ID: 25335705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study.
    Bruix J; Tak WY; Gasbarrini A; Santoro A; Colombo M; Lim HY; Mazzaferro V; Wiest R; Reig M; Wagner A; Bolondi L
    Eur J Cancer; 2013 Nov; 49(16):3412-9. PubMed ID: 23809766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
    Crona DJ; Keisler MD; Walko CM
    Ann Pharmacother; 2013 Dec; 47(12):1685-96. PubMed ID: 24259629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial.
    Argilés G; Saunders MP; Rivera F; Sobrero A; Benson A; Guillén Ponce C; Cascinu S; Van Cutsem E; Macpherson IR; Strumberg D; Köhne CH; Zalcberg J; Wagner A; Luigi Garosi V; Grunert J; Tabernero J; Ciardiello F
    Eur J Cancer; 2015 May; 51(8):942-9. PubMed ID: 25818084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial.
    Eisen T; Joensuu H; Nathan PD; Harper PG; Wojtukiewicz MZ; Nicholson S; Bahl A; Tomczak P; Pyrhonen S; Fife K; Bono P; Boxall J; Wagner A; Jeffers M; Lin T; Quinn DI
    Lancet Oncol; 2012 Oct; 13(10):1055-62. PubMed ID: 22959186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced dose of salvage-line regorafenib monotherapy for metastatic colorectal cancer in Japan.
    Hirano G; Makiyama A; Makiyama C; Esaki T; Oda H; Uchino K; Komoda M; Tanaka R; Matsushita Y; Mitsugi K; Shibata Y; Kumagai H; Arita S; Ariyama H; Kusaba H; Akashi K; Baba E
    Anticancer Res; 2015 Jan; 35(1):371-7. PubMed ID: 25550574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
    Grothey A; Van Cutsem E; Sobrero A; Siena S; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Tabernero J; Yoshino T; Lenz HJ; Goldberg RM; Sargent DJ; Cihon F; Cupit L; Wagner A; Laurent D;
    Lancet; 2013 Jan; 381(9863):303-12. PubMed ID: 23177514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study.
    Van Cutsem E; Martinelli E; Cascinu S; Sobrero A; Banzi M; Seitz JF; Barone C; Ychou M; Peeters M; Brenner B; Hofheinz RD; Maiello E; André T; Spallanzani A; Garcia-Carbonero R; Arriaga YE; Verma U; Grothey A; Kappeler C; Miriyala A; Kalmus J; Falcone A; Zaniboni A
    Oncologist; 2019 Feb; 24(2):185-192. PubMed ID: 30190299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regorafenib in Patients with Antiangiogenic-Naïve and Chemotherapy-Refractory Advanced Colorectal Cancer: Results from a Phase IIb Trial.
    Riechelmann RP; Leite LS; Bariani GM; Glasberg J; Rivelli TG; da Fonseca LG; Nebuloni DR; Braghiroli MI; Queiroz MA; Isejima AM; Kappeler C; Kikuchi L; Hoff PM
    Oncologist; 2019 Sep; 24(9):1180-1187. PubMed ID: 31175167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Regorafenib With 2/1 Schedule for Patients ≥ 75 Years With Metastatic Colorectal Cancer (mCRC) After Failure of 2 Lines of Chemotherapy.
    Petrioli R; Chirra M; Messuti L; Fiaschi AI; Savelli V; Martellucci I; Francini E
    Clin Colorectal Cancer; 2018 Dec; 17(4):307-312. PubMed ID: 29548772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Mir O; Brodowicz T; Italiano A; Wallet J; Blay JY; Bertucci F; Chevreau C; Piperno-Neumann S; Bompas E; Salas S; Perrin C; Delcambre C; Liegl-Atzwanger B; Toulmonde M; Dumont S; Ray-Coquard I; Clisant S; Taieb S; Guillemet C; Rios M; Collard O; Bozec L; Cupissol D; Saada-Bouzid E; Lemaignan C; Eisterer W; Isambert N; Chaigneau L; Cesne AL; Penel N
    Lancet Oncol; 2016 Dec; 17(12):1732-1742. PubMed ID: 27751846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse event management strategies: optimizing treatment with regorafenib in patients with metastatic colorectal cancer.
    Mitchell J; Khoukaz T; McNeal D; Brent L
    Clin J Oncol Nurs; 2014 Apr; 18(2):E19-25. PubMed ID: 24675266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylactic Effect of Dexamethasone on Regorafenib-Related Fatigue and/or Malaise: A Randomized, Placebo-Controlled, Double-Blind Clinical Study in Patients with Unresectable Metastatic Colorectal Cancer (KSCC1402/HGCSG1402).
    Tanioka H; Miyamoto Y; Tsuji A; Asayama M; Shiraishi T; Yuki S; Kotaka M; Makiyama A; Shimokawa M; Shimose T; Masuda S; Yamaguchi T; Komatsu Y; Saeki H; Emi Y; Baba H; Oki E; Maehara Y;
    Oncology; 2018; 94(5):289-296. PubMed ID: 29514163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study.
    Dane F; Ozgurdal K; Yalçın Ş; Benekli M; Aykan NF; Yücel İ; Özkan M; Evrensel T; Sevinç A; Coskun HŞ; Sanli UA; Kara IO; Yumuk PF
    BMJ Open; 2020 Mar; 10(3):e027665. PubMed ID: 32220908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib.
    Wong AL; Lim JS; Sinha A; Gopinathan A; Lim R; Tan CS; Soh T; Venkatesh S; Titin C; Sapari NS; Lee SC; Yong WP; Tan DS; Pang B; Wang TT; Zee YK; Soong R; Trnkova Z; Lathia C; Thiery JP; Wilhelm S; Jeffers M; Goh BC
    J Transl Med; 2015 Feb; 13():57. PubMed ID: 25889309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regorafenib-Induced Hypothyroidism as a Predictive Marker for Improved Survival in Metastatic or Unresectable Colorectal Cancer Refractory to Standard Therapies: A Prospective Single-Center Study.
    Kim JH; Kim SY; Kim KP; Kim TW; Chae SY; Kim HJ; Kim JS; Ryu JS; Moon DH; Kim JE; Hong YS
    Target Oncol; 2019 Dec; 14(6):689-697. PubMed ID: 31555963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Investigation of Administration Technique of Regorafenib in Our Center].
    Matsuda C; Danno K; Miyazaki S; Fujitani K; Kubota M; Motoori M; Nakatsuka R; Nishimura M; Kitagawa A; Takagi M; Iwase K
    Gan To Kagaku Ryoho; 2017 Jan; 44(1):47-51. PubMed ID: 28174379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Large-Scale, Prospective Observational Study of Regorafenib in Japanese Patients with Metastatic Colorectal Cancer in a Real-World Clinical Setting.
    Yamaguchi K; Komatsu Y; Satoh T; Uetake H; Yoshino T; Nishida T; Yamazaki N; Takikawa H; Morimoto T; Chosa M; Sunaya T; Hamada Y; Muro K; Sugihara K
    Oncologist; 2019 Jul; 24(7):e450-e457. PubMed ID: 30606885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Hand-Foot Skin Reaction with Regorafenib Efficacy in the Treatment of Metastatic Colorectal Cancer.
    Kobayashi K; Kawakami K; Yokokawa T; Aoyama T; Suzuki K; Wakatsuki T; Suenaga M; Sato H; Sugiyama E; Yamaguchi K; Hama T
    Oncology; 2019; 96(4):200-206. PubMed ID: 30763946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: A systematic review.
    Røed Skårderud M; Polk A; Kjeldgaard Vistisen K; Larsen FO; Nielsen DL
    Cancer Treat Rev; 2018 Jan; 62():61-73. PubMed ID: 29175677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.